Drug intelligence / Profile preview

JNJ-64232025

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

JNJ-64232025 is a monoclonal antibody that targets CD154, also known as CD40 ligand (CD40L). It acts as a CD40 ligand inhibitor and is being developed for the treatment of T cell-mediated autoimmune disorders. The drug is in early clinical development, with Phase 1 studies completed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants. The originator and developer of this drug is Johnson & Johnson[1][2][4].

Targets

CD40LG (CD40 ligand extracellular domain)

Beyond the preview

Go deeper on JNJ-64232025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-64232025.

Explore the full profile